Barclays PLC Buys 5,542 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Barclays PLC raised its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 3.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 180,397 shares of the company’s stock after purchasing an additional 5,542 shares during the period. Barclays PLC owned 0.59% of Fulgent Genetics worth $3,332,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in shares of Fulgent Genetics by 45.5% during the 4th quarter. GAMMA Investing LLC now owns 2,133 shares of the company’s stock valued at $39,000 after purchasing an additional 667 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Fulgent Genetics by 267.4% during the 4th quarter. Russell Investments Group Ltd. now owns 2,693 shares of the company’s stock valued at $50,000 after buying an additional 1,960 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Fulgent Genetics during the 4th quarter valued at about $57,000. R Squared Ltd purchased a new stake in shares of Fulgent Genetics during the 4th quarter valued at about $74,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Fulgent Genetics during the 4th quarter valued at about $120,000. Institutional investors own 48.06% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on FLGT. Piper Sandler decreased their target price on shares of Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. StockNews.com upgraded shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 5th.

Fulgent Genetics Price Performance

Shares of NASDAQ FLGT opened at $18.53 on Tuesday. The company has a market cap of $571.95 million, a P/E ratio of -3.36 and a beta of 1.36. Fulgent Genetics, Inc. has a 1 year low of $14.57 and a 1 year high of $25.11. The firm has a 50-day simple moving average of $17.32 and a two-hundred day simple moving average of $18.12.

Insiders Place Their Bets

In related news, CFO Paul Kim purchased 100,000 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was purchased at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the purchase, the chief financial officer now owns 348,282 shares of the company’s stock, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 31.76% of the stock is owned by insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.